Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of single ascending doses of APD 371 in healthy adult volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
Price : $35 *
At a glance
- Drugs Olorinab (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- 07 Feb 2019 According to an Arena Pharmaceuticals media release, data from the study will be presented at Crohn's & Colitis Congress 2019.
- 29 Apr 2015 Status changed from recruiting to completed, as reported in an Arena Pharmaceuticals media release.
- 29 Apr 2015 Positive results published in an Arena Pharmaceuticals media release.